

## Shield Therapeutics Enters into Exclusive License with Beijing Aosaikang Pharmaceutical in China

### Torreya advised Shield on the transaction

London, United Kingdom, and Beijing, China, January 9, 2020

Shield Therapeutics Plc (LSE: STX), a London-based commercial stage pharmaceutical company with a focus on addressing iron deficiency, entered into an exclusive license agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. ("ASK Pharma") in China, Hong Kong, Macau and Taiwan (the "Territory"). Under the agreement ASK Pharma will undertake and pay for all activities to achieve marketing authorization and commercialization in the Territory.

Shield will receive an upfront payment of US\$11.4 million and is eligible to receive a further US\$11.4 million upon regulatory approval of Feraccru®/Accrufer® in China. Shield will also receive up to US\$40 million in milestone payments upon the achievement of specified cumulative sales targets. For the duration of the intellectual property in the Territory, Shield will receive tiered ongoing royalties of 10% or 15% of net sales of Feraccru®/Accrufer®. ASK Pharm will be responsible for all clinical and regulatory costs and activities as well as all manufacturing and distribution costs of goods sold in the Territory.

Torreya advised Shield on the transaction. This is the second assignment on which Torreya has advised Shield in the past 15 months. Torreya also advised on Shield's licensing agreement with Norgine for Feraccru®/Accrufer® in Europe and certain other countries. This transaction also reinforces Torreya's strength and leadership position in China. Torreya has completed 11 transactions involving a China party since 2018. Due to its dedicated China licensing advisory team and market knowledge, Torreya has rapidly become the most active advisory firm in China licensing in the Life Sciences sector.

### ABOUT SHIELD THERAPEUTICS PLC

For more information about Shield Therapeutics, please see: [www.shieldtherapeutics.com](http://www.shieldtherapeutics.com)

### ABOUT JIANGSU AOSAIKANG PHARMACEUTICAL CO. LTD.

For more information about ASK, please see: [www.ask-pharm.com/en](http://www.ask-pharm.com/en)

### Deal Press Release

#### Torreya Contact

JIE LIU

Managing Director | New York Office

[jie.liu@torreya.com](mailto:jie.liu@torreya.com) | 917.683.4003 | [torreya.com](http://torreya.com)



Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.